KFO309 - The clinical research unit Virus Induced Lung injury

All News / Events

Ein kleines Protein gegen COVID-19


Gießener Lungenforscherinnen und -forscher testen einen Wirkstoff gegen schwere Verläufe von COVID-19 – BMBF fördert die klinische Studie mit rund 1,84 Millionen Euro

KFO309 projects are searching for PhD students


Three research groups within the Clinical research Unit (CRU) 309 “Virus-Induced Lung Injury: Pathobiology and Novel Therapeutic Strategies” at the Justus Liebig University Giessen (JLU) are currently accepting applications for part-time positions to the extent of 65 % full-time equivalent as

PhD students

Please use these links to have a closer look to the job descriptions in German:

P3 Virus-Host Interactions that drive and control respiratory ephitelial injury in coronavirus infections

P5 - Impact of Btk/WASH/Mehgalin on influenza virus infection and alceolar protein clearance

P7 - Harnessing FGF-10 Signaling to protect ER-stressed alveolar ephitelial cells against viral infection - impact on regeneration versus fibrosis

 or in English

GM-CSF study extended to COVID-19 patients


GM-CSF (granulocyte/macrophage colony-stimulating factor) was found to be highly protective in pre-clinical models of pneumonia-associated lung injury including viral infection. There is first evidence of a beneficial effect of inhaled GM-CSF in patients with severe pneumonia/ARDS.
A placebo-controlled, randomized clinical phase II investigator-initiated trial (GI-HOPE, NCT02595060) currently addresses the adjunctive therapeutic role of aerosolized GM-CSF in patients with pneumonia-related ARDS (for further details see project 9). The study was extended to COVID-19 patients, please find the BMBF report here.

Progress Reports 2020


ECCPS Seminar Room
Aulweg 130
35392 Gießen

Date Projects
Feb, 7th
13:00 - 15:00 
P1 (Bauer/Weber) and
P2 (Peteranderl/Becker)
May 29th,
13:00 - 15:00
P3 (Ziebuhr/Kracht) and
P5 (Vadász/Samakovlis)
Sept 25th,
13:00 - 15:00 
P6 (Morty/
Friebertshäuser/Ehrhardt),
and P8 (Herold/Braun)
Dec, 11th,
12:00 - 15:00

P7 (Günther/Bellusci/El Agha), P10 (Sommer/Skevaki) and
Z1 (Hain/Goesmann/
Wilhelm/Looso)

Second Funding Period for the KFO309


We are happy to announce that the KFO309 is funded by the DFG for a second funding period without any restriction for the next three years. We have one additional project now - welcome Natascha Sommer and Chrysanthi Skevaki who examnine the role of metabolic changes in T cell responses induced by viral infections that exacerbate COPD and emphysema in their P10 project.

 

KFO309 research on the cover of Pediatric Pulmonology


The KFO309 -(P6) -driven study on mouse strain susceptibility to hyperoxia, which was published in print form in the July issue of Pediatric Pulmonology, got both an Editorial, and the manuscript artwork also made the cover of the July issue of the journal.

Cover Pediatric Pilmonology